Celon Pharma S.A. (WSE:CLN)

Market Cap	1.20B
Revenue (ttm)	206.34M
Net Income (ttm)	-68.88M
Shares Out	53.86M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	130.67
Dividend	0.08 (0.36%)
Ex-Dividend Date	n/a

Volume	29,300
Average Volume	11,345
Open	21.60
Previous Close	22.20
Day's Range	21.10 - 21.95
52-Week Range	20.85 - 32.40
Beta	0.84
RSI	35.65
Earnings Date	Sep 17, 2025

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 558
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2024, Celon Pharma's revenue was 204.98 million, a decrease of -4.18% compared to the previous year's 213.92 million. Losses were -34.45 million, 22.5% more than in 2023.